Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New medical approaches in advanced ovarian cancer.
Corrado G, Palluzzi E, Bottoni C, Pietragalla A, Salutari V, Ghizzoni V, Distefano M, Scambia G, Ferrandina G. Corrado G, et al. Among authors: pietragalla a. Minerva Med. 2019 Aug;110(4):367-384. doi: 10.23736/S0026-4806.19.06139-1. Epub 2019 May 22. Minerva Med. 2019. PMID: 31124637 Review.
Emerging drugs for ovarian cancer.
Lorusso D, Pietragalla A, Mainenti S, Di Legge A, Amadio G, Scambia G. Lorusso D, et al. Among authors: pietragalla a. Expert Opin Emerg Drugs. 2010 Dec;15(4):635-52. doi: 10.1517/14728214.2010.502888. Epub 2010 Jul 7. Expert Opin Emerg Drugs. 2010. PMID: 20604741 Review.
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A. Pietragalla A, et al. Int J Gynecol Cancer. 2020 Nov;30(11):1803-1810. doi: 10.1136/ijgc-2020-001556. Epub 2020 Sep 6. Int J Gynecol Cancer. 2020. PMID: 32895312 Review.
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, Ciccarone F, Carbone V, Daniele G, Scambia G. Lorusso D, et al. Among authors: pietragalla a. Expert Opin Emerg Drugs. 2020 Dec;25(4):445-453. doi: 10.1080/14728214.2020.1836155. Epub 2020 Oct 20. Expert Opin Emerg Drugs. 2020. PMID: 33040627 Review.
Newly diagnosed ovarian cancer: Which first-line treatment?
Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G. Lorusso D, et al. Among authors: pietragalla a. Cancer Treat Rev. 2020 Dec;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub 2020 Oct 9. Cancer Treat Rev. 2020. PMID: 33068886 Review.
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G. Lorusso D, et al. Among authors: pietragalla a. Ann Oncol. 2010 Jan;21(1):61-6. doi: 10.1093/annonc/mdp266. Epub 2009 Jul 15. Ann Oncol. 2010. PMID: 19605508 Free article. Clinical Trial.
36 results